Moteur de recherche d’entreprises européennes

Financement de l’UE (15,5 M €) : Amélioration du contrôle et du traitement des maladies à médiation immunitaire en explorant l’univers des signatures tissulaires imposées par le microenvironnement et … Hor 01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »

Vue d’ensemble

Texte

Amélioration du contrôle et du traitement des maladies à médiation immunitaire en explorant l’univers des signatures tissulaires imposées par le microenvironnement et leurs corrélats dans les biopsies liquides

Immune-mediated diseases (IMIDs) are an increasing medical burden in industrialized countries worldwide. IMIDs are characterized by an enormous heterogeneity with regard to disease outcome and response to targeted therapies, which currently cannot be adequately anticipated to tailor individual patient management. Hence, mechanistic understanding of this heterogeneity and biomarkers predictive for disease control and therapy response over time are important prerequisites of a future precision medicine in IMIDs. ImmUniverse has been formed as a European transdisciplinary consortium to tackle these unmet needs and to understand the role of the crosstalk between tissue microenvironment and immune cells in disease progression and response to therapy of two different IMIDs: ulcerative colitis and atopic dermatitis. Following this unique cross-disease approach ImmUniverse will fill the gap and the limitations of current studies, which do not systematically compare the complex interactions between recirculating immune cells and the respective tissue microenvironment. The consortium will combine analysis of tissue-derived signatures with “circulating signatures” detectable in liquid biopsies, employing state-of-the-art profiling technologies corresponding to multi-Omics datasets. The project will also bring diagnostics in IMID to a new level by implementing disruptive non-invasive liquid-biopsy methodology in combination with novel, validated circulating biomarker assays which are expected to improve diagnosis, inform early in the clinical course on disease severity and progression and enable treatment response monitoring. The identified signature will be validated to monitor state/progression and response to therapy in prospective observational cohorts. Realization of these objectives will result in improvement of patient management, lead to increased patient well-being and will significantly reduce the socioeconomic burden of these diseases.


Aarhus Universitet 174 488 €
Aarhus Universitetshospital 353 596 €
AIT Austrian Institute OF Technology GmbH 2 131 236 €
Centre Hospitalier Regional Universitaire Nancy 103 784 €
Christian-Albrechts-Universitaet ZU Kiel 2 915 000 €
Eli Lilly and Company Ltd. 0,00 €
Erasmus Universitair Medisch Centrum Rotterdam 105 000 €
Eurice European Research AND Project Office GmbH 704 063 €
European Federation OF Asthma &Allergy Associations Ideell Forening 50 250 €
Forum des Patients Europeens 11 781,25 €
Glaxosmithkline Research & Development Ltd. 0,00 €
Humanitas Mirasole S.p.A. 0,00 €
Information Technology FOR Translational Medicine (Ittm) SA 400 501 €
International Federation OF Crohn'S AND Ulcerative Colitis Associations 50 313 €
Istituto Superiore Di Sanita 502 989 €
Joanneum Research Forschungsgesellschaft mbH 894 909 €
Katholieke Universiteit Leuven 516 693 €
Ludwig-Maximilians-Universitaet Muenchen 392 975 €
Novartis Pharma AG 0,00 €
Pfizer Ltd. 0,00 €
Sanofi-Aventis Deutschland GmbH 0,00 €
Scuola Superiore Di Studi Universitari E Di Perfezionamento S Anna 360 000 €
Stichting Amsterdam UMC 633 048 €
Stichting Radboud Universitair Medisch Centrum 1 096 421 €
Stichting Radboud Universiteit 0,00 €
The Chancellor Masters and Scholars of the University of Cambridge 445 294 €
Universitaet ULM 210 000 €
Universita Humanitas 1 925 508 €
Universita Vita-Salute SAN Raffaele 96 313 €
Universite Du Luxembourg 780 939 €
VIB VZW 644 900 €

https://cordis.europa.eu/project/id/853995

Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.